دورية أكاديمية

Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation

التفاصيل البيبلوغرافية
العنوان: Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation
المؤلفون: Blondel, S., Egesipe, A-L, Picardi, P., Jaskowiak, A-L, Notarnicola, M., Ragot, J., Tournois, J., Le Corf, A., Brinon, B., Poydenot, P., Georges, P., Navarro, C., Pitrez, P. R., Ferreira, L., Bollot, G., Bauvais, C., Laustriat, D., Mejat, A., De Sandre-Giovannoli, A., Levy, N., Bifulco, M., Peschanski, M., Nissan, X.
بيانات النشر: Springer Nature, 2016.
سنة النشر: 2016
مصطلحات موضوعية: Binding Sites, Cell Differentiation, Farnesyltranstransferase, Geranyltranstransferase, Humans, Lamin Type A, Molecular Docking Simulation, Osteogenesis, Pluripotent Stem Cells, Progeria, Protein Prenylation, Protein Structure, Tertiary, Pyrimidines, Small Molecule Libraries, Structure-Activity Relationship
الوصف: Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by a dramatic appearance of premature aging. HGPS is due to a single-base substitution in exon 11 of the LMNA gene (c.1824C>T) leading to the production of a toxic form of the prelamin A protein called progerin. Because farnesylation process had been shown to control progerin toxicity, in this study we have developed a screening method permitting to identify new pharmacological inhibitors of farnesylation. For this, we have used the unique potential of pluripotent stem cells to have access to an unlimited and relevant biological resource and test 21,608 small molecules. This study identified several compounds, called monoaminopyrimidines, which target two key enzymes of the farnesylation process, farnesyl pyrophosphate synthase and farnesyl transferase, and rescue in vitro phenotypes associated with HGPS. Our results opens up new therapeutic possibilities for the treatment of HGPS by identifying a new family of protein farnesylation inhibitors, and which may also be applicable to cancers and diseases associated with mutations that involve farnesylated proteins.
نوع الوثيقة: journal article
اللغة: English
العلاقة: 2041-4889
DOI: 10.1038/cddis.2015.374
الإتاحة: http://hdl.handle.net/10316/108511Test
حقوق: open access
رقم الانضمام: rcaap.com.uc.estudogeral.uc.pt.10316.108511
قاعدة البيانات: RCAAP